Beta1,3-N-acetylglucosaminyltransferase-like Protein 1: Potential Therapeutic Targets

Target Name: B3GNTL1

NCBI ID: G146712

B3GNTL1

Beta1,3-N-acetylglucosaminyltransferase-like Protein 1: Potential Therapeutic Targets

Beta1,3-N-acetylglucosaminyltransferase-like protein 1 (B3GNTL1) is a protein that is expressed in various tissues and cells in the human body. It is a member of the glycosaminyltransferase family 1 (GTF-1) and is involved in the transfer of N-acetylglucosamine (NAG) to various proteins, including glycoproteins and nucleic acids. B3GNTL1 is also known as GLT-1 and has been shown to play a role in various physiological processes, including cell signaling, inflammation, and tissue repair.

Disease and Therapy

B3GNTL1 is often associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that B3GNTL1 is overexpressed in various cancer tissues and that inhibition of B3GNTL1 has the potential to be a therapeutic approach for cancer treatment.

In addition to its potential therapeutic applications, B3GNTL1 is also a drug target for several diseases. For example, B3GNTL1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Researchers have also shown that B3GNTL1 is involved in the development of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

B3GNTL1 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that increased B3GNTL1 expression is associated with poor prognosis in various cancer types, including breast, ovarian, and colorectal cancers. In addition, B3GNTL1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease, and has been shown to be associated with the development of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Expression and Function

B3GNTL1 is a transmembrane protein that is expressed in various tissues and cells in the human body. It is a member of the glycosaminyltransferase family 1 (GTF-1) and is involved in the transfer of N-acetylglucosamine (NAG) to various proteins, including glycoproteins and nucleic acids. B3GNTL1 is expressed in a variety of tissues, including the brain, pancreas, heart, and gastrointestinal tract.

B3GNTL1 is involved in several physiological processes, including cell signaling, inflammation, and tissue repair. For example, B3GNTL1 has been shown to play a role in cell signaling, including the regulation of cell adhesion and the production of neurotransmitters. It has also been shown to be involved in the regulation of inflammation, including the production of pro-inflammatory cytokines. In addition, B3GNTL1 has been shown to play a role in tissue repair, including the regulation of cell proliferation and the production of newvillin.

Drug Development

B3GNTL1 is a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Researchers have shown that B3GNTL1 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, B3GNTL1 has been shown to be involved in the development of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

There are several approaches that researchers have used to develop drugs that target B3GNTL1, including inhibition of B3GNTL1 expression, blockade of B3GNTL1-mediated signaling pathways, and use of B3GNTL1-specific antibodies. Researchers have also shown that modulation

Protein Name: UDP-GlcNAc:betaGal Beta-1,3-N-acetylglucosaminyltransferase Like 1

Functions: Putative glycosyltransferase

The "B3GNTL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GNTL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets